147 related articles for article (PubMed ID: 27681264)
1. Targeting IFN-λ: therapeutic implications.
Eslam M; George J
Expert Opin Ther Targets; 2016 Dec; 20(12):1425-1432. PubMed ID: 27681264
[TBL] [Abstract][Full Text] [Related]
2. IFN-lambda therapy: current status and future perspectives.
Lasfar A; Zloza A; Cohen-Solal KA
Drug Discov Today; 2016 Jan; 21(1):167-171. PubMed ID: 26552337
[TBL] [Abstract][Full Text] [Related]
3. Interferon-lambda: a new addition to an old family.
Donnelly RP; Kotenko SV
J Interferon Cytokine Res; 2010 Aug; 30(8):555-64. PubMed ID: 20712453
[TBL] [Abstract][Full Text] [Related]
4. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
Aoki Y; Sugiyama M; Murata K; Yoshio S; Kurosaki M; Hashimoto S; Yatsuhashi H; Nomura H; Kang JH; Takeda T; Naito S; Kimura T; Yamagiwa Y; Korenaga M; Imamura M; Masaki N; Izumi N; Kage M; Mizokami M; Kanto T
J Gastroenterol; 2015 Aug; 50(8):894-902. PubMed ID: 25501286
[TBL] [Abstract][Full Text] [Related]
5. Interferon-λ in the context of viral infections: production, response and therapeutic implications.
Hermant P; Michiels T
J Innate Immun; 2014; 6(5):563-74. PubMed ID: 24751921
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of type III interferon expression.
Iversen MB; Paludan SR
J Interferon Cytokine Res; 2010 Aug; 30(8):573-8. PubMed ID: 20645874
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?
Galmozzi E; Viganò M; Lampertico P
Aliment Pharmacol Ther; 2014 Mar; 39(6):569-78. PubMed ID: 24461198
[TBL] [Abstract][Full Text] [Related]
8. Type III Interferons in Hepatitis C Virus Infection.
Boisvert M; Shoukry NH
Front Immunol; 2016; 7():628. PubMed ID: 28066437
[TBL] [Abstract][Full Text] [Related]
9. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
Marcello T; Grakoui A; Barba-Spaeth G; Machlin ES; Kotenko SV; MacDonald MR; Rice CM
Gastroenterology; 2006 Dec; 131(6):1887-98. PubMed ID: 17087946
[TBL] [Abstract][Full Text] [Related]
10. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
[TBL] [Abstract][Full Text] [Related]
11. IL-28 and IL-29: newcomers to the interferon family.
Uzé G; Monneron D
Biochimie; 2007; 89(6-7):729-34. PubMed ID: 17367910
[TBL] [Abstract][Full Text] [Related]
12. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
Liu B; Chen S; Guan Y; Chen L
PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
[TBL] [Abstract][Full Text] [Related]
13. The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases.
Griffiths SJ; Dunnigan CM; Russell CD; Haas JG
J Innate Immun; 2015; 7(3):231-42. PubMed ID: 25634147
[TBL] [Abstract][Full Text] [Related]
14. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
Matsuura K; Watanabe T; Tanaka Y
J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
[TBL] [Abstract][Full Text] [Related]
15. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond.
Lazear HM; Nice TJ; Diamond MS
Immunity; 2015 Jul; 43(1):15-28. PubMed ID: 26200010
[TBL] [Abstract][Full Text] [Related]
16. [Action of type III IFNs and their roles in immune responses].
Domagalski K; Tretyn A; Pawłowska M; Szczepanek J; Halota W
Postepy Hig Med Dosw (Online); 2010 Oct; 64():522-33. PubMed ID: 21109705
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning, expression, and characterization of chicken IFN -lambda.
Karpala AJ; Morris KR; Broadway MM; McWaters PG; O'Neil TE; Goossens KE; Lowenthal JW; Bean AG
J Interferon Cytokine Res; 2008 Jun; 28(6):341-50. PubMed ID: 18593329
[TBL] [Abstract][Full Text] [Related]
18. Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV.
Laidlaw SM; Dustin LB
Front Immunol; 2014; 5():545. PubMed ID: 25400636
[TBL] [Abstract][Full Text] [Related]
19. Type III interferon (IFN-lambda) antagonizes the antiviral activity of interferon-alpha in vitro.
Bordi L; Lalle E; Lapa D; Caglioti C; Quartu S; Capobianchi MR; Castilletti C
J Biol Regul Homeost Agents; 2013; 27(4):1001-9. PubMed ID: 24382181
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-λ1 contributes to its anti-HCV activity in human hepatoma cells.
Li X; Li Y; Fang S; Su J; Jiang J; Liang B; Huang J; Zhou B; Zang N; Ho W; Li J; Li Y; Chen H; Ye L; Liang H
Antiviral Res; 2017 Apr; 140():83-94. PubMed ID: 28131804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
